Phase I/II Clinical Study of Pralatrexate in Japanese Patients With Relapsed or Refractory Peripheral T-cell Lymphoma
Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 03 Aug 2017
At a glance
- Drugs Pralatrexate (Primary)
- Indications T cell lymphoma
- Focus Therapeutic Use
- Sponsors Mundipharma International
- 03 Aug 2017 Planned End Date changed from 1 Dec 2015 to NULL.
- 06 Dec 2016 Results presented at the 58th Annual Meeting and Exposition of the American Society of Hematology.
- 01 Sep 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.